AI assistant
Median Technologies Capital/Financing Update 2025
1514_ffr_2025-03-14_b68b4b95-dbfc-4adb-aa34-528cbd77e11e.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Press release – For immediate release March 14, 2025 – 5:45 pm CET
Median Technologies meets the eligibility conditions for the PEA-PME scheme
Sophia Antipolis, France – Median Technologies (FR0011049824, ALMDT) confirms its eligibility for the PEA-PME scheme in accordance with the provisions of Articles L. 221-32-2 and D. 221-113-5 and following of the Monetary and Financial Code specifying the conditions for assessing the eligibility criteria, i.e.:
- Less than 5,000 employees,
- An annual turnover of less than 1.5 billion euros or a balance sheet total of less than 2 billion euros.
Median Technologies shares therefore continue to be included in PEA-PME accounts, which for the record benefit from the same tax advantages as the traditional stock savings plan (PEA).
About Median Technologies: Pioneering innovative imaging solutions and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S.
and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Contacts
MEDIAN TECHNOLOGIES
Emmanuelle Leygues VP, Corporate Marketing & Financial Communications +33 6 10 93 58 88 [email protected]
Investors Ghislaine Gasparetto SEITOSEI ACTIFIN +33 6 21 10 49 24 [email protected] U.S. media & investors Chris Maggos COHESION BUREAU +41 79 367 6254 [email protected]
Press Caroline Carmagnol ALIZE RP +33 6 64 18 99 59 [email protected]